Gustavo Viani/sbradioterapia.com.br
Sep 8, 2025, 17:37
Gustavo Viani: Changing the Standard in High-Risk Endometrial Cancer
Gustavo Viani, Professor at the Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared a post on LinkedIn:
“PORTEC-3: Changing the Standard in High-Risk Endometrial Cancer
The gap
Until PORTEC-3, we lacked long-term evidence on whether chemoRT > RT alone in high-risk EC.
Results (10-year follow-up)
- OS: 74.4% vs 67.3% (HR 0.73)
- RFS: 72.8% vs 67.4%
- Clear benefit in p53-abn and stage III
- No added value for POLEmut or MMRd
Impact
- Molecular profiling + staging = the new way forward.
- ChemoRT is now standard for p53-abn and advanced stage patients.
Take-home
- Not all high-risk EC are equal to precision adjuvant therapy is essential.
See more.”
More posts featuring Gustavo Viani
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 8, 2025, 17:37
Sep 8, 2025, 16:57
Sep 8, 2025, 16:24
Sep 8, 2025, 15:59
Sep 8, 2025, 15:58